Liu Wanying, Chen Shaozhen, Yang Jiajie, Chen Yanxin, Yang Qinwen, Lu Lihua, Li Jiazheng, Yang Ting, Zhang Guanbin, Hu Jianda
The Second Affiliated Hospital of Fujian Medical University, Quanzhou, China; Fujian Medical University Union Hospital, Fuzhou, China.
Fujian Medical University Union Hospital, Fuzhou, China; Fujian Medical University Cancer Hospital, Fujian Cancer Hospital, Fuzhou, China.
Microb Pathog. 2025 Sep;206:107734. doi: 10.1016/j.micpath.2025.107734. Epub 2025 May 29.
Investigating the microbiota of blood and urine from acute myeloid leukemia (AML) patients is essential to unravel the complex role of microbiota in systemic host-microbe interactions and implications.
We conducted a longitudinal observational study to characterize the temporal dynamics of blood and urine microbiota in 27 AML patients, utilizing metagenomic analysis pipeline for microbial identification to identify disease-associated microbial signatures.
The composition of blood and urine microbiota of AML was dominated by Proteobacteria phylum in blood, Firmicutes phylum in urine. The species and diversity of blood and urine microbiota did not have difference between AML patients and healthy controls. Restitution of alpha and beta diversity of blood microbiota and urine microbiota to resemble that of healthy controls occurred after cessation of treatment. Temporal variation of urine microbiome was higher than blood after treatment which was closely related to pathogenic bacteria and beneficial bacteria measured by coefficient of variation (CV) of alpha diversity. The temporal variability of urine microbiota was significantly correlated with platelet and exposure of levofloxacin. The variation of microbiome of AML patients with infection was found that the relative abundance of Burkholderia significantly enriched in blood and urine which had high accuracy and sensitivity. The correlation between blood microbiota and serum amino acid metabolites was similar to that between gut microbiota and serum metabolites.
This study represents the first comprehensive investigation to quantify the longitudinal variability of blood and urine microbiota in AML patients, revealing distinct patterns compared to gut microbiota and associations with adverse clinical outcomes. Our findings highlight the potential of leveraging stabilizing taxa as a target for microbiome restoration.
研究急性髓系白血病（AML）患者血液和尿液中的微生物群对于揭示微生物群在全身宿主-微生物相互作用中的复杂作用及影响至关重要。
我们进行了一项纵向观察性研究，以表征27例AML患者血液和尿液微生物群的时间动态变化，利用宏基因组分析流程进行微生物鉴定，以识别与疾病相关的微生物特征。
AML患者血液和尿液微生物群的组成中，血液以变形菌门为主，尿液以厚壁菌门为主。AML患者与健康对照者血液和尿液微生物群的种类和多样性无差异。治疗停止后，血液微生物群和尿液微生物群的α和β多样性恢复至与健康对照者相似水平。治疗后尿液微生物组的时间变化高于血液，这与通过α多样性变异系数（CV）测量的病原菌和有益菌密切相关。尿液微生物群的时间变异性与血小板及左氧氟沙星暴露显著相关。发现感染的AML患者微生物组的变化，伯克霍尔德菌在血液和尿液中的相对丰度显著富集，具有较高的准确性和敏感性。血液微生物群与血清氨基酸代谢产物之间的相关性与肠道微生物群与血清代谢产物之间的相关性相似。
本研究首次全面调查了AML患者血液和尿液微生物群的纵向变异性，揭示了与肠道微生物群不同的模式以及与不良临床结局的关联。我们的发现突出了利用稳定分类群作为微生物组恢复靶点的潜力。
